Calviri’s Immunosignature (IMS) Technology is universally applicable to the development of diagnostic products. It is based on the recognition that combinatorial peptide sequences provide a richer source of possible antibody binding ligands than proteomic sequences, which are highly redundant. The diversity of antibody specificities is far greater than the diversity of proteomes. The IMS Technology enables an individual’s immense antibody repertoire to be broadly queried and reproducibly measured.

Our IMS approach rests on three key principles:

  • IMS engages the full antibody repertoire as disease-induced biomarkers.
  • The combinatorially-designed ligands represent a library of mimetic variants of the original epitopes that elicited the antibodies.
  • Competitive, parallel binding of antibodies to the library of IMS peptides maximizes the resolution of antibody specificities.

An immunosignature assay provides individual readouts of the many components of a person’s antibody response. This contrasts with a conventional enzyme-linked immunosorbent assay (ELISA) in which all the binding events to the whole virus or antigen in an assay-well are summed into a single readout.


Antibodies are Disease-Amplified Biomarkers

  • Our immune system is a whole-body surveillance network which  is alerted by an antigen from infection or bad cells.
  • Alerted B-cells of the immune system secrete antibodies that recognize the infection or bad cells.
  • Immunosignatures use the specificities of the proliferating antibodies to define health states.

Libraries of High-diversity Peptides Serve as Antibody-ligands

  • Proteomic sequence space is highly redundant.
  • The amino acid sequence strings comprising proteomes correspond to a very small proportion of all possible combinations.
  • Peptides can be selected to evenly sample combinatorial sequence space.

In an IMS Immunoassay, Libraries of High-diversity Peptides Serve as Antibody-ligands

  • The diverse peptides selected from combinatorial space serve as antigen mimics, recognized by antibodies.
  • The workflow of an IMS immunoassay resembles an ELISA; however the parallel, competitive antigen/ligand binding activities are unique.
  • An IMS assay results in >105 quantified data points.


Diagnostic tests for many different diseases may be possible with Calviri’s IMS technology. Many published studies have demonstrated the breadth of its application.

The application currently under evaluation is a sero-test for SARS-CoV-2, the causative agent of COVID-19. The plethora of individually measured antibody-biomarkers provides the opportunity to discern details of disease-related states that cannot be captured in a conventional, single-readout sero-test. The IMS technology enables the development of immunoassays that address more challenging clinical and epidemiological needs such as significantly greater sensitivity weeks after exposure.